Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Shares Outstanding (Weighted Average): 2013-2024

Historic Shares Outstanding (Weighted Average) for Ultragenyx Pharmaceutical (RARE) over the last 12 years, with Dec 2024 value amounting to $92.3 million.

  • Ultragenyx Pharmaceutical's Shares Outstanding (Weighted Average) rose 4.56% to $96.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.4 million, marking a year-over-year increase of 4.56%. This contributed to the annual value of $92.3 million for FY2024, which is 12.46% up from last year.
  • As of FY2024, Ultragenyx Pharmaceutical's Shares Outstanding (Weighted Average) stood at $92.3 million, which was up 12.46% from $82.1 million recorded in FY2023.
  • Ultragenyx Pharmaceutical's Shares Outstanding (Weighted Average)'s 5-year high stood at $92.3 million during FY2024, with a 5-year trough of $61.0 million in FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $82.1 million (2023), whereas its average is $81.5 million.
  • Data for Ultragenyx Pharmaceutical's Shares Outstanding (Weighted Average) shows a peak YoY grew of 17.13% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Ultragenyx Pharmaceutical's Shares Outstanding (Weighted Average) stood at $61.0 million in 2020, then rose by 11.66% to $68.2 million in 2021, then increased by 2.85% to $70.1 million in 2022, then increased by 17.13% to $82.1 million in 2023, then grew by 12.46% to $92.3 million in 2024.